Clinical trials: Relapse/Recurrence, open to volunteers
Prostate Cancer, Recurrent Prostate Cancer
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer
This is a randomized, open-label, pilot study assessing the impact of a short course of bicalutamide on PSMA expression in patients with prostate cancer belonging to the intermediate unfavorable or high risk group, who have low…
- Conditions
- Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent
- Trial name
- NCT07593079
- Testing
- Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
This phase II trial tests how well pirtobrutinib and mosunetuzumab work in treating patients with grade 1-3a follicular lymphoma (FL) that has come back after a period of improvement (relapsed) or that has not responded to…
- Conditions
- Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT06948786
- Testing
- Pirtobrutinib, Mosunetuzumab, Biospecimen Collection
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed
A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue
The purpose of this study is to determine if the addition of infusions of a type of immune cell called a "natural killer", or NK cell to the sarcoma chemotherapy regimen GEM/DOX (gemcitabine and docetaxel) can improve outcomes in…
- Trial name
- TINKS (NCT05634369)
- Testing
- GEM/DOX + TGFBi expanded NK cells
- Where
- 22 sites in United States
- Volunteers
- 50 people
- Sponsor
- Nationwide Children's Hospital
Hepatocellular Carcinoma
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA
The goal of the REMNANT study is to confirm the clinical value of detecting a new biomarker, ctDNA (circulating tumor DNA), in the follow-up of patients with operated liver cancer.
- Trial name
- REMNANT (NCT05375370)
- Testing
- circulating tumor DNA dosage
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Rouen
Alcohol Use Disorder
New Relapse Model in Psychiatry
The goal of this clinical trial is to learn about risk factors of relapse in patients with alcohol use disorder. The main questions it aims to answer are : Among patients with Alcohol Use Disorder, are there clusters of patients…
- Trial name
- NRMP (NCT06244641)
- Testing
- Auto-questionnaires, hetero-questionnaires and Evoked-potentials
- Where
- Belgium
- Volunteers
- 350 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Non-Muscle Invasive Bladder Carcinoma, Recurrent Bladder Carcinoma
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
This phase II trial is being done to develop and test a healthy eating program to reduce cancer recurrence (cancer that has come back after a period of improvement) and/or progression (cancer that is growing, spreading, or…
- Conditions
- Non-Muscle Invasive Bladder Carcinoma, Recurrent Bladder Carcinoma, Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8
- Trial name
- NCT06733363
- Testing
- Behavioral Dietary Intervention, Telephone- Based Intervention
- Where
- United States
- Volunteers
- 344 people
- Sponsor
- Roswell Park Cancer Institute
High Risk Biochemical Recurrence (BCR), Deutenzalutamide Soft Capsules
A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer
This is a multicenter, randomized, double- blind, placebo-controlled Phase III trial to evaluate the efficacy and safety of Deutenzalutamide plus ADT versus placebo plus ADT in patients with high-risk biochemical recurrence (BCR)…
- Trial name
- NCT07875881
- Testing
- Deutenzalutamide Soft Capsules + ADT
- Where
- 3 sites in China
- Volunteers
- 1,044 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Hodgkin Lymphoma, Relapse
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
Despite the progress in the therapy, Hodgkin's Lymphoma (HL) remains fatal for more than 15% of patients. Even in patients who are cured, the morbidity of therapy is substantial and long-lasting.
- Conditions
- Hodgkin Lymphoma, Relapse, Refractory
- Trial name
- NCT06090864
- Testing
- Chemotherapy, Cell infusion
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced / Metastatic Solid Tumor
A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint…
- Trial name
- NCT06063681
- Testing
- SR-8541A, Immune checkpoint inhibitor (ICI)
- Where
- 3 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Stingray Therapeutics
Ischemic Stroke, Digital Health
Prevention of Ischemic Stroke Recurrence Using Digital Technology Application
The goal of this study is to find out whether a comprehensive management program that uses a smart bracelet and a mobile app can help people who have had an ischemic stroke (a type of stroke caused by a blocked blood vessel in…
- Trial name
- DESIRE (NCT07825311)
- Testing
- Digital Prevention Management, Usual Stroke Secondary Prevention Management
- Where
- China
- Volunteers
- 1,696 people
- Sponsor
- Affiliated Hospital of Nantong University
Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia
A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia
This clinical trial is a multicenter, single-arm, open-label study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of olutasidenib administered orally twice daily under fasting conditions for one cycle of…
- Trial name
- NCT07604064
- Testing
- Olutasidenib
- Where
- Japan
- Volunteers
- 3 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Alcohol Use Disorder, Alcohol Abuse
Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder
Alcohol Use Disorders are currently positioned as the third leading cause of preventable death in the United States, constituting a humanitarian crisis with substantial financial burden on society and medical facilities.
- Conditions
- Alcohol Use Disorder, Alcohol Abuse, Alcoholism, Drinking Behavior
- Trial name
- NCT06415721
- Testing
- Active Transcranial Magnetic Simulation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- VA Palo Alto Health Care System
Non-Muscle-Invasive Bladder Cancer
HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer
The purpose of this study is to determine the efficacy and safety of Hyperthermic Intravesical Chemotherapy (HIVEC) with Gemcitabine (GEM) after Transurethral Resection of Bladder Tumors (TURBT) in the treatment of medium or…
- Trial name
- NCT06327932
- Testing
- TURBT, HIVEC, Intravesical Chemotherapy
- Volunteers
- 320 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
This study is conducted to evaluate the efficacy and safety of SHR-8068 combined with Adebrelimab and Apatinib compared with Adebrelimab combined with Apatinib in perioperative treatment of resectable hepatocellular carcinoma…
- Trial name
- NCT07682272
- Testing
- SHR-8068 Injection, Adebrelimab Injection, Apatinib Mesylate Tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia
Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
Relapsed or refractory acute leukemia (R/R AL) is a life-threatening blood cancer with poor outcomes and limited treatment options.
- Conditions
- Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Trial name
- R/R AL (NCT07696481)
- Testing
- PID23 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhujiang Hospital
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
The rationale for the new sequence of pulsed dose chemotherapy proposed in this trial is based on the hypotheses that current standard dosing of chemotherapy plus pembrolizumab ultimately suppresses the immune system and has a…
- Trial name
- NCT06052839
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dan Zandberg
Cervical Cancer, Recurrent
A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer
This is a Phase II clinical trial to evaluate the safety and efficacy of Utidelone, a genetically engineered epothilone derivative, combined with Toripalimab, a PD-1 inhibitor, in patients with recurrent or metastatic cervical…
- Conditions
- Cervical Cancer, Recurrent, Metastatic
- Trial name
- NCT07363330
- Testing
- Utidelone plus Toripalimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Zhongnan Hospital
Endometrial Cancer, Cervical Cancer
The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study.
The role of small-volume lymph node disease (ITC and micro metastases) among patients with endometrial or cervical cancer submitted to sentinel node (SLN) procedure is not clearly defined.
- Conditions
- Endometrial Cancer, Cervical Cancer, Sentinel Lymph Node, Micrometastasis
- Trial name
- ITCMicroUtCa (NCT04403867)
- Testing
- Sentinel lymph node (SLN) biosy +/- lymphadenectomy
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Prostate Cancer
Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)
Significant advances in molecular nuclear medicine imaging in prostate cancer have been achieved in recent years. In particular, the introduction of prostate-specific membrane antigen (PSMA) -based tracers has significantly…
- Trial name
- ProsTone (NCT04271579)
- Testing
- Salvage Lymphnode dissection
- Where
- Germany
- Volunteers
- 397 people
- Sponsor
- Martini-Klinik am UKE GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.